SequelSEC

MIMEDX GROUP, INC. MDXG

Surgical & Medical Instruments & Apparatus · CIK 0001376339 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$355.17M
Fiscal year ended 2026-06-30
Operating income
$8.75M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

MIMEDX GROUP, INC. (MDXG) reported revenue of $355.17M and net income of $6.24M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from MIMEDX GROUP, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

MIMEDX GROUP, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$355.17M
Cost of revenue$75.12M
Gross profit$280.05M
Operating income$8.75M
Net income$6.24M
Research & development$15.38M
Weighted-average diluted sharesUnavailable
Pretax income$11.53M
Income tax expense$5.29M
Diluted EPSUnavailable
Selling, general & administrative$255.08M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

MIMEDX GROUP, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$135.84M
Total assets$281.00M
Current assets$205.36M
Total liabilities$65.00M
Current liabilities$38.50M
Total equity incl. NCI$216.00M
Temporary (mezzanine) equityUnavailable
Inventory$20.93M
Accounts receivable$41.30M
Goodwill$19.44M
Long-term debt$15.71M
Accounts payable$8.29M

Cash flow

MIMEDX GROUP, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$46.15M
Capital expendituresUnavailable
Investing cash flow-$11.87M
Financing cash flow-$17.31M
Net change in cash$16.97M
Stock-based compensation$6.59M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

MIMEDX GROUP, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin78.8%
Operating margin2.5%
FCF marginUnavailable
SBC / revenue1.9%
Current ratio5.33x
Revenue YoY growth-2.4%
Net margin1.8%
R&D / revenue4.3%
CapEx / revenueUnavailable
Long-term debt / equity0.07x
Effective tax rate45.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MDXG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-29View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.